Conferences

UCLA's Division of Rheumatology was well represented at the 2021 ACR Convergence with 23 posters, 5 abstracts, 3 plenaries, 3 industry sessions, 3 community sessions, 1 review course, and 1 study group. Congratulations to the faculty and fellows who contribute to the presentations this year!

Posters:

• ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis(Link is external) (Link opens in new window)
• Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis(Link is external) (Link opens in new window)
• Economic and Healthcare Resource Use Burden of Systemic Sclerosis(Link is external) (Link opens in new window)
• Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials(Link is external) (Link opens in new window)
• Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON(Link is external) (Link opens in new window)
• Decreased HDL Levels and Antioxidant Function in Juvenile Dermatomyositis(Link is external) (Link opens in new window)
• Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies(Link is external) (Link opens in new window)
• Lower HDL-associated Apolipoprotein A-I Levels Associate with Presence of Calcinosis in Adult Dermatomyositis(Link is external) (Link opens in new window)
• Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics(Link is external) (Link opens in new window)
• Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?(Link is external) (Link opens in new window)
• Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial(Link is external) (Link opens in new window)
• Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis(Link is external) (Link opens in new window)
• Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment(Link is external) (Link opens in new window)
• NLP-Based Clustering Methods Can Efficiently Categorize Scientific Abstracts for Medical Conferences(Link is external) (Link opens in new window)
• “What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care(Link is external) (Link opens in new window)
• Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis(Link is external) (Link opens in new window)
• Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey(Link is external) (Link opens in new window)
• Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis(Link is external) (Link opens in new window)
• Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial(Link is external) (Link opens in new window)
• Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease(Link is external) (Link opens in new window)
• Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial(Link is external) (Link opens in new window)
• Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis(Link is external) (Link opens in new window)
• Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa(Link is external) (Link opens in new window)

Plenaries:

• Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend(Link is external) (Link opens in new window)
• Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors(Link is external) (Link opens in new window)
• Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features(Link is external) (Link opens in new window)

Oral Abstract Sessions:

• Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)(Link is external) (Link opens in new window)
• Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib(Link is external) (Link opens in new window)
• Trends in Adverse Pregnancy Outcomes Among Women with Systemic Sclerosis in the United States(Link is external) (Link opens in new window)
• Clinical Heterogeneity of the VEXAS Syndrome: A Case Series(Link is external) (Link opens in new window)
• The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors(Link is external) (Link opens in new window)

Review Courses:

• Impact of Rheumatic Disease Management on Cardiovascular Risk(Link is external) (Link opens in new window)

Study Groups:

• Humanities in Medicine – Rheum for More Insight(Link is external) (Link opens in new window)

Industry Sessions:

• SAPHNELO™ (anifrolumab-fnia): The First-in Class Type 1 Interferon (IFN-1) Signaling Inhibitor(Link is external) (Link opens in new window)
• Treatment Priorities in Systemic Lupus Erythematosus: Focus on Musculoskeletal Symptoms and Patient-Reported Outcomes(Link is external) (Link opens in new window)
• Woman Leaders in Rheumatology: Leadership in a Virtual World(Link is external) (Link opens in new window)

Community Hub Sessions:

• CH Ultrasound: The Business of MSUS(Link is external) (Link opens in new window)
• CH SLE: Meet the Masters: Reflections on Lupus in 2021?(Link is external) (Link opens in new window)
• CH Leadership: Cocktail Hour: Creating the Ideal Work / Life Balance?(Link is external) (Link opens in new window)